These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31810594)

  • 1. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine.
    Tsui JI; Mayfield J; Speaker EC; Yakup S; Ries R; Funai H; Leroux BG; Merrill JO
    J Subst Abuse Treat; 2020 Feb; 109():80-85. PubMed ID: 31810594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine.
    Tsui JI; Stephens D; Collins B; Denisiuk E; Hallgren KA; Blalock KL; Klein JW; Jack HE; Merrill JO
    J Addict Med; 2023 Jul-Aug 01; 17(4):491-492. PubMed ID: 37579119
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to: "Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine".
    Englander H
    J Addict Med; 2023 Jul-Aug 01; 17(4):492-493. PubMed ID: 37579120
    [No Abstract]   [Full Text] [Related]  

  • 4. Methamphetamine use and illicit opioid use during buprenorphine treatment.
    Kratina-Hathaway Z; Radick AC; Leroux BG; Blalock K; Kim TW; Darnton J; Saxon AJ; Samet JH; Tsui JI
    J Subst Use Addict Treat; 2023 Aug; 151():. PubMed ID: 37811395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
    Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
    Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine Drug Test Results Among Adolescents and Young Adults in an Outpatient Office-Based Opioid Treatment Program.
    Ramey OL; Bonny AE; Silva Almodóvar A; Nahata MC
    J Adolesc Health; 2023 Jul; 73(1):141-147. PubMed ID: 37031090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine use and setting type among reproductive-aged women self-reporting nonmedical prescription opioid use.
    DeSisto CL; Terplan M; Kacha-Ochana A; Green JL; Mueller T; Cox S; Ko JY
    J Subst Use Addict Treat; 2023 Dec; 155():209083. PubMed ID: 37245854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data - Characteristics associated with two measures of retention and patterns of care over time.
    Banta-Green CJ; Hansen RN; Ossiander EM; Wasserman CR; Merrill JO
    J Subst Abuse Treat; 2021 Aug; 127():108446. PubMed ID: 34049724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Add-on Buprenorphine to Matrix Program in Reduction of Craving and Relapse Among People With Methamphetamine Use Disorder: A Randomized Controlled Trial.
    Kheirabadi GR; Bahrami M; Shariat A; Tarrahi M
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):45-48. PubMed ID: 33347022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial.
    Stein M; Herman D; Conti M; Anderson B; Bailey G
    Addiction; 2020 Jan; 115(1):82-94. PubMed ID: 31430414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.